High expression of TMEM180, a novel tumour marker, is associated with poor survival in stage III colorectal cancer

These results indicate that TMEM180 is a useful marker for clinical prognosis in patients with CRC. We believe that these fundamental data warrant further basic and translational studies of TMEM180, and its mAb, for development of therapeutics against CRC.